Unknown

Dataset Information

0

Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naive patients with active psoriatic arthritis (PsA): results from SPIRIT-P1.


ABSTRACT: To evaluate the efficacy and safety of ixekizumab alone or with concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) versus placebo in patients with active psoriatic arthritis (PsA) as part of a SPIRIT-P1 subgroup analysis (NCT01695239).Patients were stratified by cDMARD use (concomitant cDMARDs use (including methotrexate) or none (past or naïve use)) and randomly assigned to treatment groups (ixekizumab 80?mg every 4 weeks (IXEQ4W) or every 2 weeks (IXEQ2W) or placebo). Efficacy was evaluated versus placebo at week 24 by the American College of Rheumatology criteria (ACR20/50/70), modified total Sharp score and Health Assessment Questionnaire-Disability Index (HAQ-DI). Safety was assessed according to cDMARD status.Regardless of concomitant cDMARD usage, ACR20, ACR50 and ACR70 response rates were significantly higher versus placebo with IXEQ4W and IXEQ2W. The proportion of patients achieving HAQ-DI minimal clinically important difference was significantly higher versus placebo with IXEQ4W with concomitant cDMARD use and IXEQ2W, regardless of concomitant cDMARD use. Treatment-emergent adverse events (AE) were more frequent versus placebo for either ixekizumab-dosing regimen, regardless of concomitant cDMARD use. Serious AEs were not higher versus placebo, regardless of concomitant cDMARD use.Ixekizumab treatment improved measures of disease activity and physical function in patients with active PsA relative to placebo, when used with or without concomitant cDMARD therapy.

SUBMITTER: Coates LC 

PROVIDER: S-EPMC5743900 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature

altmetric image

Publications

Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1.

Coates Laura C LC   Kishimoto Mitsumasa M   Gottlieb Alice A   Shuler Catherine L CL   Lin Chen-Yen CY   Lee Chin Hyok CH   Mease Philip J PJ  

RMD open 20171222 2


<h4>Objective</h4>To evaluate the efficacy and safety of ixekizumab alone or with concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) versus placebo in patients with active psoriatic arthritis (PsA) as part of a SPIRIT-P1 subgroup analysis (NCT01695239).<h4>Methods</h4>Patients were stratified by cDMARD use (concomitant cDMARDs use (including methotrexate) or none (past or naïve use)) and randomly assigned to treatment groups (ixekizumab 80 mg every 4 weeks (IXEQ4W) or every  ...[more]

Similar Datasets

| S-EPMC6152421 | biostudies-literature
| S-EPMC7839215 | biostudies-literature
| S-EPMC7516094 | biostudies-literature
| S-EPMC8572272 | biostudies-literature
| S-EPMC7695764 | biostudies-literature
| S-EPMC10654305 | biostudies-literature
| S-EPMC5264219 | biostudies-literature
| S-EPMC7688884 | biostudies-literature
| S-EPMC9348611 | biostudies-literature
| S-EPMC6199530 | biostudies-literature